DLL3 and small cell lung carcinoma: The first clinical experience investigating an ADC targeting DLL3, rovalpituzumab tesirine (Rova-T), was halted after interesting preliminary results in the treatment of SCLC, due to a lack of efficacy in phase 3 studies [16].